{{Drugbox
| Verifiedfields = changed
| Watchedfields = 
| verifiedrevid = 477243306
| IUPAC_name = (''Z'')-4-(1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenol
| image = Afimoxifene2DACS.svg
| width = 250px

<!--Clinical data-->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = Experimental
| routes_of_administration = [[Topical administration|Topical]] ([[gel]])

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!-- Identifiers -->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 68392-35-8
| CAS_supplemental = 
| ATC_prefix = 
| ATC_suffix = 
| ATC_supplemental = 
| PubChem = 449459
| IUPHAR_ligand = 
| DrugBank_Ref = 
| DrugBank = 
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 395987
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 17197F0KYM
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D06551
| ChEBI = 
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 489

<!--Chemical data-->
| C=26 | H=29 | N=1 | O=2
| molecular_weight = 387.5139 g/mol
| SMILES = CC\C(c1ccccc1)=C(c2ccc(OCCN(C)C)cc2)/c3ccc(O)cc3
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C26H29NO2/c1-4-25(20-8-6-5-7-9-20)26(21-10-14-23(28)15-11-21)22-12-16-24(17-13-22)29-19-18-27(2)3/h5-17,28H,4,18-19H2,1-3H3/b26-25-
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = TXUZVZSFRXZGTL-QPLCGJKRSA-N
| synonyms = 4-Hydroxytamoxifen
}}

'''Afimoxifene''',<ref name="AMA_USAN">{{cite web | url = http://www.ama-assn.org/ama1/pub/upload/mm/365/afimoxifene.pdf | title = Statement on a nonproprietary name adopted by the USAN council: Afimoxifene | accessdate = 2008-03-26 | date = | format = | work = | publisher = American Medical Association | pages = | language = | archiveurl = | archivedate = | quote = }}</ref> also known as '''4-hydroxytamoxifen''' ('''4-OHT''', '''4-HT''', '''OHTAM''', others), is a [[selective estrogen receptor modulator]] (SERM) of the [[triphenylethylene]] group and the major [[active metabolite]] of [[tamoxifen]].<ref name="AdisInsight">http://adisinsight.springer.com/drugs/800019175</ref><ref name="Desta_2004">{{cite journal |vauthors =Desta Z, Ward BA, Soukhova NV, Flockhart DA|title=Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6|journal= J Pharmacol Exp Ther |volume= 310 |issue= 3 |pages= 1062–1075 |year= 2004 | doi = 10.1124/jpet.104.065607 |pmid= 15159443}}</ref> The drug is under development under the tentative trademark '''TamoGel''' as a [[topical medication|topical]] [[gel]] for the treatment of [[hyperplasia]] of the [[breast]].<ref name="AdisInsight" /><ref name="JatoiRody2016">{{cite book|author1=Ismail Jatoi|author2=Achim Rody|title=Management of Breast Diseases|url=https://books.google.com/books?id=f9iCDQAAQBAJ&pg=PA77|date=16 November 2016|publisher=Springer|isbn=978-3-319-46356-8|pages=77–}}</ref> It has completed a [[Phases of clinical research#Phase II|phase II]] [[clinical trial]] for [[mastalgia|cyclical mastalgia]],<ref name="pmid17351746">{{cite journal | vauthors = Mansel R, Goyal A, Nestour EL, Masini-Etévé V, O'Connell K | title = A phase II trial of Afimoxifene (4-hydroxytamoxifen gel) for cyclical mastalgia in premenopausal women | journal = Breast Cancer Res. Treat. | volume = 106 | issue = 3 | pages = 389–397 | year = 2007 | pmid = 17351746 | doi = 10.1007/s10549-007-9507-x }}</ref> but further studies are required before afimoxifene can be approved for this indication and marketed.<ref name="JatoiRody2016" />

A study in France on 55&nbsp;women showed that rubbing afimoxifene on the skin was as effective as oral tamoxifen at slowing [[breast cancer]] growth. A United States trial will compare 6 weeks use before breast cancer surgery. Skin application can reduce systemic levels by a factor of nine and this is expected to reduce the unpleasant side-effects of tamoxifen.{{cn|date=April 2017}}

In addition to its [[antiestrogen]]ic and [[estrogen]]ic activity, afimoxifene has been found to act as an [[receptor antagonist|antagonist]] of the [[estrogen-related receptor]]s (ERRs) [[ERRβ]] and [[ERRγ]].<ref name="Levine2011">{{cite book|author=Alice C. Levine|title=Hormones and Cancer: Breast and Prostate, An Issue of Endocrinology and Metabolism Clinics of North America,|url=https://books.google.com/books?id=ZabQAQAAQBAJ&pg=PT271|date=3 October 2011|publisher=Elsevier Health Sciences|isbn=1-4557-1239-6|pages=271–}}</ref><ref name="Khetan2014">{{cite book|author=Sushil K. Khetan|title=Endocrine Disruptors in the Environment|url=https://books.google.com/books?id=s2ajAwAAQBAJ&pg=PT104|date=23 May 2014|publisher=Wiley|isbn=978-1-118-89115-5|pages=104–}}</ref>

==See also==
* [[List of investigational hormonal agents#Estrogenics|List of investigational hormonal agents § Estrogenics]]
* [[Droloxifene]] (3-hydroxytamoxifen)
* [[Endoxifen]] (N-desmethyl-4-hydroxytamoxifen)
* [[Norendoxifen]] (N-didesmethyl-4-hydroxytamoxifen)

==References==
{{Reflist|30em}}

==External links==
* {{MeshName|4-hydroxytamoxifen}}


{{Estrogen receptor modulators}}
{{Nuclear receptor modulators}}

[[Category:Human drug metabolites]]
[[Category:Phenol ethers]]
[[Category:Selective estrogen receptor modulators]]
[[Category:Triphenylethylenes]]


{{pharma-stub}}